In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found myriad genetic drivers ...

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung ...

A Minnesota jury has found Merck and several cosmetic talc manufacturers liable in a mesothelioma lawsuit. The verdict ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health pharmaceuticals across various areas, including Keytruda, Keytruda Qlex, Welireg, ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock ...

The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

View Merck & Co., Inc. MRK stock quote prices, financial information, real-time forecasts, and company news from CNN.

Merck said on Monday its ​experimental ‌drug met the main goals of a late-stage ‌trial ​in ⁠patients with a ⁠cancer of the ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...